title: Effects of chronic treatment with amlodipine in streptozotocin-diabetic and spontaneously hypertensive rats.
abstract: Calcium antagonists have been reported to alter insulin secretion and insulin sensitivity. However, there still exists a controversy over the benefits of calcium antagonists in the conditions when diabetes mellitus and hypertension coexist. In the present study the effects of six-week chronic amlodipine treatment (5 mg kg-1 p.o.) on insulin sensitivity and serum lipid levels in streptozotocin (STZ)-diabetic and spontaneously hypertensive (SH) rats were investigated. Intravenous injection of STZ produced glucosuria (> 2%). hyperglycaemia, hypoinsulinemia, polydipsia, polyphagia, loss of body weight, hypercholesterolemia, hypertriglyceridaemia, hypertension and bradycardia. SH rats were found to have significantly higher insulin levels compared to their Wistar controls. Treatment of rats with amlodipine in diabetic and diabetic-hypertensive animals significantly prevented STZ-induced loss of body weight, hypertension and bradycardia. It also significantly prevented STZ-induced hyperglycaemia in both STZ-diabetic Wistar and SH rats. The insulin levels were decreased in the non-diabetic treated Wistar rats but were unaltered in the non-diabetic SH and the diabetic Wistar and SH rats. There was a significant reduction in cholesterol levels in diabetic Wistar and SH rats. In conclusion the present study revealed beneficial effects of amlodipine treatment in hyperinsulinemic, diabetic and/or hypertensive rats.
authors.affiliation: Department of Pharmacology, L.M. College of Pharmacy, Navrangpura, Ahmedabad, India.
authors.forename: P S
authors.initials: PS
authors.lastname: Srinivasan
authors.forename: Z S
authors.initials: ZS
authors.lastname: Hakim
authors.forename: D D
authors.initials: DD
authors.lastname: Santani
authors.forename: R K
authors.initials: RK
authors.lastname: Goyal
mesh_terms: D017311:Amlodipine / Q000494:pharmacology*; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000494:pharmacology*; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000503:physiopathology*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006973:Hypertension / Q000097:blood / Q000503:physiopathology*; D007328:Insulin / Q000097:blood; D007333:Insulin Resistance / Q000502:physiology; D008055:Lipids / Q000097:blood; D051381:Rats; D011918:Rats, Inbred SHR; D017208:Rats, Wistar; D015430:Weight Gain
chemical_list: D001786:Blood Glucose; D002121:Calcium Channel Blockers; D007328:Insulin; D008055:Lipids; D017311:Amlodipine